As the pan-European STOXX Europe 600 Index remains relatively flat, with mixed performances across major stock indexes, investors are paying close attention to economic indicators such as the eurozone's inflation reaching the European Central Bank’s 2% target and a steady labor market. In this environment, identifying promising small-cap stocks often involves looking for companies with strong fundamentals that can capitalize on stable economic conditions and potential insider actions that might signal confidence in future growth.
Top 10 Undervalued Small Caps With Insider Buying In Europe
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Kitwave Group | 13.0x | 0.3x | 45.29% | ★★★★★☆ |
| Foxtons Group | 13.4x | 1.1x | 37.95% | ★★★★★☆ |
| A.G. BARR | 19.1x | 1.8x | 47.41% | ★★★★☆☆ |
| Hoist Finance | 8.7x | 1.8x | 19.55% | ★★★★☆☆ |
| Seeing Machines | NA | 2.8x | 45.61% | ★★★★☆☆ |
| NOTE | 20.2x | 1.3x | -12.10% | ★★★☆☆☆ |
| Absolent Air Care Group | 25.3x | 2.0x | 45.12% | ★★★☆☆☆ |
| CVS Group | 45.2x | 1.3x | 38.43% | ★★★☆☆☆ |
| Karnov Group | 223.1x | 4.7x | 32.11% | ★★★☆☆☆ |
| John Mattson Fastighetsföretagen | 8.7x | 7.5x | -120.10% | ★★★☆☆☆ |
Let's review some notable picks from our screened stocks.
Kitwave Group (AIM:KITW)
Simply Wall St Value Rating: ★★★★★☆
Overview: Kitwave Group is a wholesale distributor specializing in ambient, foodservice, and frozen & chilled products with a market cap of £0.19 billion.
Operations: Kitwave Group generates revenue primarily from its Ambient, Foodservice, and Frozen & Chilled segments. The company's cost of goods sold (COGS) has been a significant component of its expenses, with operating expenses also contributing to the financial structure. Notably, Kitwave's gross profit margin has shown an upward trend over recent periods, reaching 22.78% as of April 2025.
PE: 13.0x
Kitwave Group, a smaller company in Europe, has seen its sales rise to £376.21 million for the half-year ending April 2025, up from £296.96 million the previous year. Despite this growth in sales, net income dipped to £4.18 million from £5.08 million. The company increased its interim dividend to 4 pence per share and demonstrated insider confidence with significant share purchases over recent months. However, high external debt remains a concern alongside volatile share prices recently observed over three months.
- Navigate through the intricacies of Kitwave Group with our comprehensive valuation report here.
Gain insights into Kitwave Group's historical performance by reviewing our past performance report.
Pharmanutra (BIT:PHN)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Pharmanutra is a company specializing in the development and commercialization of nutraceutical products, with a market cap of €1.03 billion.
Operations: The company generates revenue primarily from its operations in Italy (€70.24 million) and foreign markets (€39.34 million), with a smaller contribution from Akern (€5.92 million). Over recent periods, the gross profit margin has shown an upward trend, reaching 51% by the end of 2024. Operating expenses have been increasing, notably in sales and marketing, which were €18.49 million by the end of 2024.
PE: 27.7x
Pharmanutra, a European small cap, has caught attention with insider confidence shown through share purchases over the past year. This pharmaceutical company is navigating its industry with external borrowing as its sole funding source, which adds risk but also potential for growth. Earnings are projected to grow by 15.72% annually, suggesting future expansion opportunities. Despite financial risks from funding choices, the insider activity hints at belief in Pharmanutra's long-term prospects and value within its sector.
- Unlock comprehensive insights into our analysis of Pharmanutra stock in this valuation report.
Assess Pharmanutra's past performance with our detailed historical performance reports.
Breedon Group (LSE:BREE)
Simply Wall St Value Rating: ★★★★★★
Overview: Breedon Group is a construction materials company with operations in cement, aggregates, asphalt, and ready-mixed concrete across Great Britain, Ireland, and the United States, with a market cap of £1.32 billion.
Operations: The company's revenue is primarily derived from segments in Great Britain (£997.40 million), Ireland (£233.40 million), the United States (£132.50 million), and Cement (£309.20 million). Notably, its gross profit margin has shown significant fluctuations, reaching as high as 82.31% in recent periods, indicating varying efficiency levels in managing production costs relative to sales revenue over time.
PE: 14.0x
Breedon Group, a construction materials company, highlights its potential as an undervalued opportunity among European small caps. Recent insider confidence was demonstrated with purchases made in the first quarter of 2025. The company's revenue for Q1 2025 rose by 9% year-over-year, aided by acquisitions despite adverse weather impacting operations in the USA. Earnings are projected to grow annually at nearly 16%, though reliance on external borrowing poses some financial risk.
Turning Ideas Into Actions
- Get an in-depth perspective on all 62 Undervalued European Small Caps With Insider Buying by using our screener here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Pharmanutra might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com